Cucurbitacin E targets proliferating endothelia

Journal of Surgical Research

Volumn 69, Issue 1, 1997, Pages 55-60

  Duncan, Mark D ^a,b   Duncan, Kimberly L K ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CUCURBITACIN E; CUCURBITACIN GLYCOSIDE; NSC 106399; PHALLOIDIN; RHODAMINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CELL PROLIFERATION; CONFERENCE PAPER; DEPOLYMERIZATION; DRUG DETERMINATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYPOTHESIS; PRIORITY JOURNAL; TARGET CELL; TUMOR VASCULARIZATION;

EID: 0031127782     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1997.5028     Document Type: Conference Paper

References (22)

1. 1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1: 27-31, 1995.
2. 2. Kerbel, R. S. Inhibition of tumour angiogenesis as a strategy to circumvent acquired resistance to anticancer therapeutic agents. BioEssays 13: 31-36, 1991.
3. 3. Jaffe, E. A., Nachman, R. L., Becker, C. G., et al. Culture of human endothelial cells derived from umbilical veins. J. Clin. Invest. 52: 2745-2756, 1973.
4. 4. Takahashi, K., Sawasaki, Y., Hata, J. I., Mukai, K., and Goto, T. Spontaneous transformation and immortalization of human endothelial cells. In Vitro Cell Dev. Biol. 25: 265-274, 1990.
5. 5. Lavie, D., and Glotter, E. The cucurbitanes, a group of tetracyclic triterpenes. Fortschr. Chem. Org. Naturst. 29: 307-362, 1971.
6. 6. Duncan, K. L. K., Duncan, M. D., Alley, M. C., and Sausville, E. A. Cucurbitacin E induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells. Biochem. Pharmacol. 52: 1553-1560, 1996.
7. 7. Edery, H., Schatzberg-Porath, G., and Gitter, S. Pharmacodynamic activity of elatericin (cucurbitacin D). Arch. Int. Pharmacodyn. 130: 315-335, 1961.
8. 8. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., and Vaigro-Wolff, A. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer. Inst. 83: 757-766, 1991.
9. 9. Howard, T. H., and Oresajo, C. O. The kinetics of chemotactic peptide-induced change in F-actin content, F-actin distribution and the shape of neutrophils. J. Cell Biol. 101: 1078-1085, 1985.
10. 10. Gottlieb, A. I., Langille, B. L., Wong, M. K. K., and Kim, D. W. Biology of disease: Structure and function of the endothelial cytoskeleton. Lab. Invest. 65: 123-137, 1991.
11. 11. O'Neill, F. J. Control of nuclear division and chromosomal abnormalities in cytochalasin B-treated normal and transformed cells. In S. W. Tannenbaum (Ed.), Cytochalasins: Biochemical and Cell Biological Aspects. New York: Elsevier, 1978. Pp. 217-253.
12. 12. Sollott, S. J., Cheng, L., Pauly, R. R., Jenkins, G. M., Monticone, R. E., Kuzuya, M., Froehlich, J. P., Crow, M. T., Lakatta, E. G., Rowinsky, E. K., and Kinsella, J. L. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J. Clin. Invest. 95: 1869-1876, 1995.
13. 13. Saville, M. W., Lietzau, J., Pluda, J. M., Feuerstein, I., Odom, J., Wilson, W. H., Humphrey, R. W., Feigel, E., Steinberg, S. M., Broder, S., and Yarchoan, R. Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 346: 26-28, 1995.
14. 14. Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M. R., Viale, G., Giavazzi, R., and Taraboletti, G. The microtubule affecting drug paclitaxel has anti-angiogenic activity. Clin. Cancer Res. 2: 1843-1849, 1996.
15. 15. Blickenstaff, R. T. Sterols and cucurbitacins. In R. T. Blickenstaff (Ed.), Antitumor Steroids. New York: Academic Press, 1992. Pp. 187-191.
16. 16. Bousquet, P. F., Paulsen, L. A., Fondy, C., Lipski, K. M., Loucy, K. J., and Fondy, T. P. Effects of cytochalasin B in culture and in vivo on murine Madison 109 lung carcinoma and on B16 melanoma. Cancer Res. 50: 1430-1439, 1990.
17. 17. Hart, I. R., Raz, A., and Fidler, I. J. Effect of cytoskeleton-disrupting agents on the metastatic behavior of melanoma cells. J. Natl. Cancer Inst. 64: 891-900, 1980.
18. FAK) in prostate carcinoma. J. Surg. Res. 63: 359-363, 1996.
19. 19. Bai, R., Pettit, G. R., and Hamel, E. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J. Biol. Chem. 265: 17141-17145, 1990.
20. 20. Pettit, G. R., Singh, S. B., Boyd, M. R., Hamel, E., Pettit, R. K., Schmidt, J. M., and Hogan, F. Antineoplastic agents. 291. Isolation and synthesis of Combretastatins A-4, A-5, and A-6. J. Med. Chem. 38: 1666-1672, 1995.
21. 21. Bubb, M. R., Senderowitz, A. M. J., Sausville, E. A., Duncan, K. L. K., and Korn, E. D. Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. J. Biol. Chem. 269: 14869-14871, 1994.
22. 22. Bai, R., Paull, K. D., Herald, C. L., Pettit, G. R., and Hamel, E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. J. Biol. Chem. 266: 15882-15889, 1991.